Pyroxamide

Pyroxamide

SCHEMBL154681

O=C(CCCCCCC(=O)Nc1cccnc1)NO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 1.00
HDAC8 Q9BY41 7/20 1.00
HDAC2 Q92769 7/20 1.00
HDAC11 Q96DB2 6/20 1.00
HDAC6 Q9UBN7 6/20 1.00
HDAC4 P56524 5/20 1.00
HDAC7 Q8WUI4 5/20 1.00
HDAC9 Q9UKV0 5/20 1.00
HDAC5 Q9UQL6 5/20 1.00
HDAC3 O15379 5/20 1.00
HDAC10 Q969S8 5/20 1.00
POLB P06746 2/20 0.76
LMNA P02545 1/20 0.76
NCOR2 Q9Y618 2/20 0.67
KDM4E B2RXH2 1/20 0.67
BRD4 O60885 1/20 0.67
NCOR1 O75376 1/20 0.67
NR1I2 O75469 1/20 0.67
EGFR P00533 1/20 0.67
CYP3A4 P08684 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5956924 1.00 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC11HDAC6
Pyroxamide SCHEMBL30184775 1.00 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC11HDAC6
SCHEMBL15480449 0.94 HDAC3 (0.88) HDAC1HDAC8HDAC2HDAC11HDAC6
SCHEMBL8277953 0.88 HDAC3 (0.78) HDAC1HDAC8HDAC2HDAC11HDAC6
SCHEMBL13477810 0.88 LMNA (0.81) HDAC1HDAC8HDAC2HDAC11HDAC6
SCHEMBL823590 0.87 HDAC3 (0.76) HDAC1HDAC8HDAC2HDAC11HDAC6
SCHEMBL16596336 0.87 LMNA (1.00) HDAC1HDAC8HDAC2HDAC11HDAC6
SCHEMBL823570 0.87 LMNA (1.00) HDAC1HDAC8HDAC2HDAC11HDAC6
SCHEMBL30444393 0.87 LMNA (1.00) HDAC1HDAC8HDAC2HDAC11HDAC6
SCHEMBL14415898 0.87 LMNA (1.00) HDAC1HDAC8HDAC2HDAC11HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2987 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107052-A1 COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) 2026-05-21 WO claimed
US-20260125650-A1 METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES TRAILHEAD BIOSYSTEMS INC (US) 2026-05-07 US claimed
EP-4691479-A2 GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE Janssen Biotech, Inc. (US) 2026-02-11 EP claimed
US-20260007676-A1 HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES VIRACTA THERAPEUTICS INC (US) 2026-01-08 US claimed
EP-4448107-B1 DRUG DELIVERY SYSTEMS BASED ON ENDOPEROXIDES USEFUL IN DIAGNOSIS AND THERAPY, AND METHODS THEREOF FACULDADE DE FARMACIA DA UNIV DE LISBOA (PT) 2025-11-05 EP claimed
EP-4640714-A2 METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST PML Screening, LLC (US) 2025-10-29 EP claimed
EP-4194548-B1 GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE JANSSEN BIOTECH INC (US) 2025-10-22 EP claimed
CN-120189514-A Use of HDAC inhibitors in the treatment of liver cancer 浙江大学绍兴研究院 2025-06-24 CN claimed
US-20250161243-A1 MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS THE SCRIPPS RESEARCH INSTITUTE 2025-05-22 US claimed
WO-2025106604-A1 COMPOSITIONS AND METHODS RELATING TO ANTIVIRAL THERAPEUTICS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2025-05-22 WO claimed
US-20040018968-A1 Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-01-29 US claimed
WO-2004009771-A2 STENTS CAPABLE OF CONTROLLABLY RELEASING HISTONE DEACETYLASE INHIBITORS ADVANCED STENT TECHNOLOGIES, INC. (US) 2004-01-29 WO claimed
WO-2003088954-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2003-10-30 WO claimed
WO-2003083067-A2 HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS AND ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2003-10-09 WO claimed
WO-2003075839-A2 METHODS OF INDUCING TERMINAL DIFFERENTIATION ATON PHARMA, INC. (US) 2003-09-18 WO claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-20030144340-A1 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2003-07-31 US claimed
EP-1297851-A1 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy Board of Regents, The University of Texas System (US) 2003-04-02 EP claimed
WO-2002090534-A1 METHOD FOR TREATING NEURODEGENERATIVE, PSYCHIATRIC AND OTHER DISORDERS WITH DEACETYLASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2002-11-14 WO claimed
WO-2002085400-A1 COMPOSITIONS AND METHODS FOR REESTABLISHING GENE TRANSCRIPTION THROUGH INHIBITION OF DNA METHYLATION AND HISTONE DEACETYLASE SUPERGEN, INC. (US) 2002-10-31 WO claimed